Standardization of an orthotopic mouse brain tumor model following transplantation of CT-2A astrocytoma cells

R. Martínez-Murillo and A. Martínez

Department of Cellular, Molecular, and Developmental Neurobiology, Instituto Cajal, Madrid, Spain

Offprint requests to: Alfredo Martinez, Department of Cellular, Molecular, and Developmental Neurobiology, Instituto Cajal, Avda. Doctor Arce 37, 28002 Madrid, Spain. e-mail: amartinez@cajal.csic.es


Summary. Animal models of glial-derived neoplasms are needed to study the biological mechanisms of glioma tumorigenesis and those that sustain the disease state. With the aim to develop and characterize a suitable in vivo experimental mouse model for infiltrating astrocytoma, with predictable and reproducible growth patterns that recapitulate human astrocytoma, this study was undertaken to analyze the long-term course of a syngeneic orthotopically implanted CT-2A mouse astrocytoma in C57BL/6J mice. Intracranial injection of CT-2A cells into caudate-putamen resulted in development of an aggressive tumor showing typical features of human glioblastoma multiforme, sharing close histological, immunohistochemical, proliferative, and metabolic profiles. To simulate metastatic disease to the brain, CT-2A cells were injected through the internal carotid artery. Tumors identical to those obtained by intracranial injection were obtained. Finally, CT-2A cells were re-isolated from experimental brain tumors and transcranially re-injected into the caudate-putamen of healthy mice. These cells generated new tumors that were indistinguishable from the initial ones, suggesting in vivo self-renewal of tumor cells. Small-animal models are essential for testing novel biological therapies directed against relevant molecular targets. In a preliminary study, experimental CT-2A tumors were chronically treated with the small molecule 77427, a gastrin-releasing peptide (GRP) blocker compound that inhibits angiogenesis. Treated animals developed significantly smaller tumors than controls, suggesting an antitumor action for 77427 in glioblastomas. We conclude that the orthotopic CT-2A tumor model, as described herein, is appropriate to explore the mechanisms of glioma development and for preclinical trials of promising drugs. Histol Histopathol 22, 1309-1326 (2007)

Key words: Astrocytoma, Animal model, Antiangiogenic treatment, Metastasis, Magnetic resonance imaging (MRI)

DOI: 10.14670/HH-22.1309